Search
ledipasvir
Indications:
- used in combination with sofosbuvir in an experimental treatment of hepatitis C infection (genotype 1)
Mechanism of action:
- antiviral protease inhibitor, inhibits NS5A
General
antiviral agent
Database Correlations
PUBCHEM cid=71720849
References
- Lawitz E et al
Sofosbuvir and ledipasvir fixed-dose combination with and
without ribavirin in treatment-naive and previously treated
patients with genotype 1 hepatitis C virus infection (LONESTAR):
an open-label, randomised, phase 2 trial.
The Lancet, Early Online Publication, 5 November 2013
PMID: 24209977
http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(13)62121-2/abstract
Component-of
ledipasvir/sofosbuvir (Harvoni)